BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. (Q50614050)

16 March 2018

editorial

0 references

title

BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. (English)

1 reference

16 March 2018

myeloproliferative disorders

main subject

1 reference

1

1 reference

16 March 2018

Jean-Luc Villeval

14

1 reference

16 March 2018

author name string

G Q Daley

2

1 reference

16 March 2018

A R Green

3

1 reference

16 March 2018

T P Hughes

4

1 reference

16 March 2018

C Jamieson

5

1 reference

16 March 2018

P Manley

6

1 reference

16 March 2018

T Mughal

7

1 reference

16 March 2018

D Perrotti

8

1 reference

16 March 2018

J Radich

9

1 reference

16 March 2018

R Skoda

10

1 reference

16 March 2018

S Soverini

11

1 reference

16 March 2018

W Vainchenker

12

1 reference

16 March 2018

S Verstovsek

13

1 reference

16 March 2018

J M Goldman

15

1 reference

16 March 2018

publication date

1 November 2008

1 reference

16 March 2018

published in

Leukemia

1 reference

16 March 2018

volume

22

1 reference

16 March 2018

issue

11

1 reference

16 March 2018

page(s)

1975-1989

1 reference

16 March 2018

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

cites work

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

ATR-Chk1 axis protects BCR/ABL leukemia cells from the lethal effect of DNA double-strand breaks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

The interacting pathways for prevention and repair of oxidative DNA damage

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

Overexpression of the zinc finger protein MZF1 inhibits hematopoietic development from embryonic stem cells: correlation with negative regulation of CD34 and c-myb promoter activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Clonal origin of chronic myelocytic leukemia in man

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR-ABL-positive lymphoblastoid cells display limited proliferative capacity under in vitro culture conditions

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

bcr-abl, the hallmark of chronic myeloid leukaemia in man, induces multiple haemopoietic neoplasms in mice.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Reversibility of acute B-cell leukaemia induced by BCR-ABL1.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Persistence of chromosomal abnormalities additional to the Philadelphia chromosome after Philadelphia chromosome disappearance during imatinib therapy for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Emergence of clonal cytogenetic abnormalities in Ph- cells in some CML patients in cytogenetic remission to imatinib but restoration of polyclonal hematopoiesis in the majority

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

A gain-of-function mutation of JAK2 in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2V617F expression in murine hematopoietic cells leads to MPD mimicking human PV with secondary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Characterization of murine JAK2V617F-positive myeloproliferative disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Molecular pathogenesis and therapy of polycythemia induced in mice by JAK2 V617F.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Development of ET, primary myelofibrosis and PV in mice expressing JAK2 V617F

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Transgenic expression of JAK2V617F causes myeloproliferative disorders in mice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Somatic mutations of JAK2 exon 12 in patients with JAK2 (V617F)-negative myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Increased risks of polycythemia vera, essential thrombocythemia, and myelofibrosis among 24,577 first-degree relatives of 11,039 patients with myeloproliferative neoplasms in Sweden

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Polycythemia vera is not initiated by JAK2V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Extending Jak2V617F and MplW515 mutation analysis to single hematopoietic colonies and B and T lymphocytes.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

NPM1-mutated acute myeloid leukaemia occurring in JAK2-V617F+ primary myelofibrosis: de-novo origin?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The frequency of JAK2 exon 12 mutations in idiopathic erythrocytosis patients with low serum erythropoietin levels

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Progenitors homozygous for the V617F mutation occur in most patients with polycythemia vera, but not essential thrombocythemia.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Anaemia characterises patients with myelofibrosis harbouring Mpl mutation.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Fusion tyrosine kinases: a result and cause of genomic instability

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Chronic myeloid leukaemia as a model of disease evolution in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The biology of CML blast crisis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Instability of BCR-ABL gene in primary and cultured chronic myeloid leukemia stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Reactive oxygen species, DNA damage, and error-prone repair: a model for genomic instability with progression in myeloid leukemia?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL oncogenic kinase promotes unfaithful repair of the reactive oxygen species-dependent DNA double-strand breaks

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL inhibits mismatch repair to protect from apoptosis and induce point mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

p210 BCR/ABL kinase regulates nucleotide excision repair (NER) and resistance to UV radiation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

DNA double strand break repair in mammalian cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL regulates mammalian RecA homologs, resulting in drug resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL modifies the kinetics and fidelity of DNA double-strand breaks repair in hematopoietic cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL promotes accumulation of chromosomal aberrations induced by oxidative and genotoxic stress

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Expression of the p210BCR-ABL oncoprotein drives centrosomal hypertrophy and clonal evolution in human U937 cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Pharmacological inhibition of c-Abl compromises genetic stability and DNA repair in Bcr-Abl-negative cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Fusion tyrosine kinases induce drug resistance by stimulation of homology-dependent recombination repair, prolongation of G(2)/M phase, and protection from apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Chronic myeloproliferative disorders: the role of tyrosine kinases in pathogenesis, diagnosis and therapy.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Expression of a homodimeric type I cytokine receptor is required for JAK2V617F-mediated transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Oncogenic mechanisms in myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Cytogenetic studies at diagnosis in polycythemia vera: clinical and JAK2V617F allele burden correlates

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Constitutive activation of STAT5 and Bcl-xL overexpression can induce endogenous erythroid colony formation in human primary cells

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Activated Jak2 with the V617F point mutation promotes G1/S phase transition

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2 stimulates homologous recombination and genetic instability: potential implication in the heterogeneity of myeloproliferative disorders.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2-V617F and BCR-ABL--double jeopardy?

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Insights into JAK2-V617F mutation in CML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Mutagenesis and carcinogenesis caused by the oxidation of nucleic acids.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: a prospective study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Part I: mechanisms of resistance to imatinib in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

High-sensitivity detection of BCR-ABL kinase domain mutations in imatinib-naive patients: correlation with clonal cytogenetic evolution but not response to therapy

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Imatinib mesylate (STI571) inhibits growth of primitive malignant progenitors in chronic myelogenous leukemia through reversal of abnormally increased proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Discontinuation of imatinib therapy after achieving a molecular response

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Persistence of malignant hematopoietic progenitors in chronic myelogenous leukemia patients in complete cytogenetic remission following imatinib mesylate treatment

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Evidence of ABL-kinase domain mutations in highly purified primitive stem cell populations of patients with chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

High-throughput oncogene mutation profiling in human cancer

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Resistance to imatinib mesylate in chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Chronic myeloid leukemia: molecular monitoring in clinical practice

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Kinase domain mutants of Bcr-Abl exhibit altered transformation potency, kinase activity, and substrate utilization, irrespective of sensitivity to imatinib

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

AMN107 (nilotinib): a novel and selective inhibitor of BCR-ABL

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Comparison of imatinib mesylate, dasatinib (BMS-354825), and nilotinib (AMN107) in an N-ethyl-N-nitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Comparative analysis of two clinically active BCR-ABL kinase inhibitors reveals the role of conformation-specific binding in resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107)

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Tyrosine kinases as therapeutic targets in BCR-ABL negative chronic myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Gene expression changes associated with progression and response in chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Overexpression of SOCS-2 in advanced stages of chronic myeloid leukemia: possible inadequacy of a negative feedback mechanism

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Molecular profiling of CD34+ cells identifies low expression of CD7, along with high expression of proteinase 3 or elastase, as predictors of longer survival in patients with CML.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Beta-catenin stabilization stalls the transition from double-positive to single-positive stage and predisposes thymocytes to malignant transformation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JunB deficiency leads to a myeloproliferative disorder arising from hematopoietic stem cells.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Mzf1 controls cell proliferation and tumorigenesis

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Convergence of Wnt, beta-catenin, and cadherin pathways

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR/ABL kinase induces self-mutagenesis via reactive oxygen species to encode imatinib resistance

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Chromosomal rearrangements and microRNAs: a new cancer link with clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR-ABL suppresses C/EBPalpha expression through inhibitory action of hnRNP E2.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

From mRNA metabolism to cancer therapy: chronic myelogenous leukemia shows the way.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Genetic and epigenetic silencing of microRNA-203 enhances ABL1 and BCR-ABL1 oncogene expression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Genomic profile of chronic myelogenous leukemia: Imbalances associated with disease progression

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Activating alleles of JAK3 in acute megakaryoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

MK-0457, a novel kinase inhibitor, is active in patients with chronic myeloid leukemia or acute lymphocytic leukemia with the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

SGX393 inhibits the CML mutant Bcr-AblT315I and preempts in vitro resistance when combined with nilotinib or dasatinib.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Structural basis for the autoinhibition of c-Abl tyrosine kinase

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

CD13/APN regulates endothelial invasion and filopodia formation

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Lestaurtinib (CEP701) is a JAK2 inhibitor that suppresses JAK2/STAT5 signaling and the proliferation of primary erythroid cells from patients with myeloproliferative disorders

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Erlotinib effectively inhibits JAK2V617F activity and polycythemia vera cell growth

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Efficacy of TG101348, a selective JAK2 inhibitor, in treatment of a murine model of JAK2V617F-induced polycythemia vera.

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Selective inhibition of JAK2-driven erythroid differentiation of polycythemia vera progenitors

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

TG101348, a JAK2-selective antagonist, inhibits primary hematopoietic cells derived from myeloproliferative disorder patients with JAK2V617F, MPLW515K or JAK2 exon 12 mutations as well as mutation negative patients

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations

1 reference

https://api.crossref.org/works/10.1038%2FLEU.2008.231

7 January 2021

Identifiers

DOI

10.1038/LEU.2008.231

1 reference

16 March 2018

Dimensions Publication ID

1042905464

0 references

Fatcat ID

release_x4sudt5jxzgidii756dzgilnia

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/x4sudt5jxzgidii756dzgilnia

24 November 2022

mapped directly with Wikidata item

1 reference

16 March 2018